List view / Grid view
22 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces the next step in the clinical development of idarucizumab, the investigational antidote for rapid reversal of dabigatran-induced anticoagulation...
20 May 2014 | By Boehringer Ingelheim
Data analyses presented at the Annual American Thoracic Society International Conference 2014 reconfirm the efficacy of SPIRIVA® (tiotropium) in reducing the risk of COPD exacerbations...
19 May 2014 | By Boehringer Ingelheim
Results from the Phase III INPULSIS™ trials, published online in the New England Journal of Medicine, show nintedanib* significantly slowed disease progression in patients with idiopathic pulmonary fibrosis...
15 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new overall survival results from a post-hoc analysis combining the data of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
8 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference, Nice, France...
7 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference...
6 May 2014 | By Boehringer Ingelheim
Connexios Life Sciences and Boehringer Ingelheim announced an exclusive global research collaboration agreement for AMPK agonists for the treatment of patients with Type 2 Diabetes...
30 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim Animal Health reinforces its commitment to support applied research for the improved control of PRRS (Porcine Reproductive and Respiratory Syndrome) in Europe...
24 April 2014 | By Boehringer Ingelheim
Hydra Biosciences, Inc. and Boehringer Ingelheim jointly announced that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors...
17 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the US Food and Drug Administration and the European Commission have granted volasertib* ‘orphan drug designation' for the treatment of patients with acute myeloid leukaemia...
15 April 2014 | By Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim is pleased with the 2013 financial year...
8 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved Pradaxa® (dabigatran etexilate) for the treatment of DVT and PE...
24 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim has announced that new findings from ongoing Pradaxa® research will be presented during the American College of Cardiology's 63rd Annual Scientific Session...
21 March 2014 | By Boehringer Ingelheim
Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults...
14 March 2014 | By Boehringer Ingelheim
More than 73 percent of physicians surveyed said the complexity of Type 2 Diabetes is underestimated...
